XML 47 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Acquisitions Acquisitions (Details Textual) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Feb. 12, 2015
Business Acquisition [Line Items]      
Contingent consideration $ 238.5us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases $ 0us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases  
Convergence Pharmaceuticals      
Business Acquisition [Line Items]      
Cash portion of consideration 200.1us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
   
Potential future milestone payments     450.0biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
Contingent consideration 238.5us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
   
Discount rate 2.00%us-gaap_FairValueInputsDiscountRate
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
   
In-process research and development and other intangible assets     424.6us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
Convergence Pharmaceuticals | CNV1014802      
Business Acquisition [Line Items]      
Potential future milestone payments     350.0biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
/ us-gaap_ProductOrServiceAxis
= biib_CNV1014802Member
Discount rate 11.00%us-gaap_FairValueInputsDiscountRate
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
/ us-gaap_ProductOrServiceAxis
= biib_CNV1014802Member
   
Remaining cost to complete CNV1014802     143.0us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
/ us-gaap_ProductOrServiceAxis
= biib_CNV1014802Member
In-process research and development and other intangible assets     170.0us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
/ us-gaap_ProductOrServiceAxis
= biib_CNV1014802Member
Convergence Pharmaceuticals | Neuropathic pain indications      
Business Acquisition [Line Items]      
Remaining cost to complete CNV1014802     $ 446.0us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
/ us-gaap_BusinessAcquisitionAxis
= biib_ConvergencePharmaceuticalsMember
/ us-gaap_ProductOrServiceAxis
= biib_NeuropathicpainindicationsMember